Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Vir Biotechnology, Inc. (VIR) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Vir Biotechnology, Inc. (VIR) lobbying for?
Summary of the Lobbying Data:
Vir Biotechnology, Inc. hired three lobbying firms – Vir Biotechnology, W Strategies, Inc., and Forbes-Tate – to lobby on a variety of general and specific issues related to taxation, government, health, Medicare/Medicaid, science/technology, and budget/appropriations. The specific issues they lobbied on include COVID funding, pandemic preparedness funding, COVID-19 response and COVID-19 therapeutics procurement, Disease X Act, flu vaccine act, appropriations for FY 2023, education around infectious disease therapies related to COVID-19, research and development expensing, physician fee schedule related to COVID therapeutics, coverage and reimbursement of COVID-19 therapeutics, and American-made medicine act. They lobbied several government agencies, including the National Institutes of Health, Office of Science & Technology Policy, House of Representatives, Department of Health & Human Services, Senate, and Centers For Medicare and Medicaid Services.
One could infer that Vir Biotechnology, Inc. is lobbying on these specific issues because they are interested in obtaining funding, support, and regulatory approvals for their COVID-19-related therapeutics and antibody technology platform. They are also interested in securing tax incentives for their research and development activities, as well as reimbursement and coverage for their COVID-19 therapeutics. Additionally, they are advocating for legislation and appropriations that benefit their business interests and R&D competitiveness.
